The label that lets you treat yourself

A label built for a person with no help

This site covers several drug labels: the document a prescriber reads, the sticker a pharmacy puts on a bottle, and why that sticker often carries no usable directions. All of them assume a professional somewhere in the chain.

The over-the-counter label is the exception. It is written on the premise that nobody is going to explain anything, so everything a person needs has to be on the package.

That premise produces the most tightly specified label in American drug regulation. A single section sets out the headings, their order, and in many cases the exact words.

It also applies broadly. The section covers "the labeling of all OTC drug products," and where a monograph or regulation conflicts with it, this section is the one to follow unless specifically provided otherwise.

The headings, in a fixed order

The content requirements are a sequence, and the regulation says the information appears "in the order listed."

It opens with the title, "Drug Facts". Where the labeling runs onto more than one panel, the title "Drug Facts (continued)" appears at the top of each subsequent panel.

Then come active ingredients with the quantity per dosage unit, purposes, and uses. Products marketed without discrete dosage units, such as topicals, state the proportion rather than the quantity of each active ingredient.

Warnings follow, then directions, then other information, then inactive ingredients. The last heading is optional, and it is a question: "Questions?" or "Questions or comments?", followed by a telephone number.

Warnings written as sentences you finish

The warnings section is where the format does its most interesting work, because the subheadings are written as the openings of sentences.

Contraindications sit under "Do not use", in bold. The regulation says these "are absolute," intended for situations where a person should not use the product unless a doctor has made a prior diagnosis, or should not use it under any circumstances.

Preexisting conditions and symptoms sit under "Ask a doctor before use if you have", in bold. Interactions sit under "Ask a doctor or pharmacist before use if you are".

Side effects and things to avoid sit under "When using this product". Signs that mean stopping sit under "Stop use and ask a doctor if". Each heading is a fragment the reader completes with the item beneath it.

The named warnings and their own subheadings

Some warnings are not left to the manufacturer to phrase. The regulation lists categories, each with a subheading it must follow, highlighted in bold.

They include a Reye's syndrome warning for products containing salicylates, allergic reaction warnings under "Allergy alert:", an asthma warning under "Asthma alert:", and a flammability warning under a signal word.

Others cover choking, liver and stomach bleeding, sore throat, a dosage warning for products containing sodium phosphates, and a sexually transmitted diseases alert for certain vaginal products.

Topical products not intended for ingestion carry "For external use only" in bold type. And two warnings apply generally: a pregnancy and breast-feeding warning, and the keep out of reach of children warning with the accidental overdose statement.

A reporting line built into the label

One provision is unusual, because it puts the agency's own contact details onto a commercial package, and it is conditional.

It applies to over-the-counter products under an approved drug application whose packaging does not include a toll-free number for consumers to report complaints to the manufacturer or distributor.

Where that is the case, the regulation requires specific text immediately after the subheading about stopping use. It reads: "side effects occur. You may report side effects to FDA at 1-800-FDA-1088."

The regulation even fixes how small it may be. That telephone number "must appear in a minimum 6-point bold letter height or type size."

Both ingredient lists, and the cosmetic crossover

Over-the-counter labeling requires the inactive ingredients as well as the active ones, which is more than a prescription vial usually shows a patient.

Where the product is a drug and not also a cosmetic, the inactive ingredients are listed in alphabetical order.

Where the same product is also a cosmetic, the ordering rule changes. The regulation sends the reader to the cosmetic labeling rules for how those ingredients are listed and how their names are determined.

That crossover is worth knowing for anything sold as a treatment cream. One product can be both categories at once, and the label then follows two rulebooks rather than one.

What "Purpose" is actually asking for

One heading is easy to skim and turns out to be the most informative line on many packages.

Under "Purpose", the label states the general pharmacological category or the principal intended action of the drug. Where there is more than one active ingredient, it does that for each of them.

So the label separates two things that marketing usually merges. Uses are the indications. Purpose is what the ingredient is doing, ingredient by ingredient.

A product with several active ingredients and one vague purpose line has skipped a required distinction, and reading the two headings against each other is a quick test of a package.

Why this matters on a peptide page

Nothing here decides whether any particular product belongs in this category, and this site does not place any compound inside or outside it.

What the section provides is a benchmark. It is what a regulator considers the minimum for a product a person will use with no clinician involved at all.

Set that against how peptide products are usually presented. A standardized heading order, a purpose stated per active ingredient, a full inactive ingredient list, contraindications marked as absolute, and a reporting route printed on the package.

The comparison is the useful part. Where a page invites you to make your own decision, the over-the-counter label is the published example of what that normally requires.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations section 201.66, Format and content requirements for over-the-counter (OTC) drug product labeling — the scope at (a), the definitions at (b), the ordered content requirements at (c)(1) through (c)(9) including the Drug Facts title, active ingredients and proportion for products without discrete dosage units, purposes, uses, the standardized warning subheadings and named warnings, directions, other information, inactive ingredients and the optional questions heading, and the format requirements at (d) — Electronic Code of Federal Regulations, Office of the Federal Register, July 2011